Amicus Historical Balance Sheet

FOLD Stock

USD 9.49 0.30 3.26%

Trend analysis of Amicus Therapeutics balance sheet accounts such as Other Assets of 41.8 M or Common Stock Shares Outstanding of 319.6 M provides information on Amicus Therapeutics' total assets, liabilities, and equity, which is the actual value of Amicus Therapeutics to its prevalent stockholders. By breaking down trends over time using Amicus Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Amicus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Amicus Therapeutics is a good buy for the upcoming year.

Amicus Therapeutics Inventory

124.72 Million

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

About Amicus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Amicus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Amicus Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Amicus Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Amicus currently owns. An asset can also be divided into two categories, current and non-current.

Amicus Therapeutics Balance Sheet Chart

At present, Amicus Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 114.7 M, whereas Total Stockholder Equity is forecasted to decline to about 170.7 M.

Other Assets Other Stockholder Equity Other Current Liab Net Tangible Assets Capital Lease Obligations Net Working Capital

Add Fundamental

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Capital Lease Obligations

Amicus Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Amicus Therapeutics asset purchases. For example, Amicus Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Amicus Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most accounts from Amicus Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 114.7 M, whereas Total Stockholder Equity is forecasted to decline to about 170.7 M.

	2022	2023	2024	2025 (projected)
Total Liabilities	601.1M	617.7M	591.0M	299.1M
Other Stockholder Equity	2.7B	2.8B	2.9B	3.1B

Total Liab Other Stockholder Equity

Amicus Therapeutics balance sheet Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Short Term Investments	Other Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross
Total Assets		0.84	-0.61	0.47	0.7	0.59	0.95	0.45	0.8	0.46	0.7	0.56	0.56	0.73	0.6	0.64	0.43	0.56	0.5	0.86	0.61	0.64	0.84	0.7	0.93	0.52
Total Stockholder Equity	0.84		-0.3	0.37	0.43	0.35	0.62	0.07	0.52	0.7	0.38	0.77	0.26	0.49	0.44	0.31	0.42	0.37	0.22	0.73	0.52	0.31	0.83	0.47	0.6	0.25
Retained Earnings	-0.61	-0.3		-0.02	-0.99	-0.98	-0.7	-0.85	-0.94	-0.2	-0.88	-0.17	-0.8	-0.97	-0.88	-0.97	0.29	-0.87	-0.89	-0.27	-0.74	-0.95	-0.61	-0.97	-0.64	-0.94
Other Assets	0.47	0.37	-0.02		0.09	-0.11	0.46	-0.14	0.27	0.21	0.36	0.07	-0.04	0.1	0.03	0.08	0.59	-0.01	-0.12	0.62	-0.01	0.1	0.26	0.09	0.5	-0.03
Common Stock Shares Outstanding	0.7	0.43	-0.99	0.09		0.98	0.75	0.82	0.97	0.28	0.89	0.26	0.77	1.0	0.89	0.96	-0.19	0.88	0.87	0.38	0.75	0.95	0.69	1.0	0.69	0.93
Other Stockholder Equity	0.59	0.35	-0.98	-0.11	0.98		0.65	0.84	0.91	0.24	0.82	0.24	0.78	0.97	0.89	0.95	-0.33	0.88	0.89	0.24	0.76	0.93	0.63	0.97	0.58	0.93
Total Liab	0.95	0.62	-0.7	0.46	0.75	0.65		0.6	0.85	0.26	0.79	0.36	0.66	0.76	0.61	0.73	0.37	0.59	0.59	0.81	0.57	0.74	0.72	0.74	0.99	0.6
Other Current Liab	0.45	0.07	-0.85	-0.14	0.82	0.84	0.6		0.77	-0.28	0.75	-0.09	0.76	0.79	0.65	0.83	-0.19	0.65	0.75	0.24	0.49	0.81	0.33	0.8	0.56	0.78
Total Current Liabilities	0.8	0.52	-0.94	0.27	0.97	0.91	0.85	0.77		0.32	0.94	0.25	0.75	0.97	0.87	0.92	0.0	0.85	0.77	0.55	0.75	0.91	0.7	0.96	0.8	0.89
Accounts Payable	0.46	0.7	-0.2	0.21	0.28	0.24	0.26	-0.28	0.32		0.19	0.63	0.01	0.32	0.38	0.17	0.07	0.37	0.13	0.3	0.5	0.15	0.62	0.3	0.21	0.23
Cash	0.7	0.38	-0.88	0.36	0.89	0.82	0.79	0.75	0.94	0.19		0.05	0.74	0.88	0.82	0.87	0.01	0.79	0.65	0.49	0.71	0.85	0.58	0.88	0.75	0.86
Short Term Investments	0.56	0.77	-0.17	0.07	0.26	0.24	0.36	-0.09	0.25	0.63	0.05		0.31	0.32	0.29	0.26	0.03	0.23	0.36	0.3	0.42	0.28	0.85	0.28	0.33	0.07
Other Current Assets	0.56	0.26	-0.8	-0.04	0.77	0.78	0.66	0.76	0.75	0.01	0.74	0.31		0.77	0.8	0.84	-0.34	0.79	0.78	0.18	0.8	0.82	0.65	0.74	0.59	0.79
Common Stock	0.73	0.49	-0.97	0.1	1.0	0.97	0.76	0.79	0.97	0.32	0.88	0.32	0.77		0.9	0.94	-0.16	0.88	0.85	0.41	0.77	0.93	0.73	1.0	0.7	0.91
Property Plant Equipment	0.6	0.44	-0.88	0.03	0.89	0.89	0.61	0.65	0.87	0.38	0.82	0.29	0.8	0.9		0.84	-0.28	0.98	0.73	0.27	0.92	0.8	0.67	0.89	0.54	0.95
Short Long Term Debt Total	0.64	0.31	-0.97	0.08	0.96	0.95	0.73	0.83	0.92	0.17	0.87	0.26	0.84	0.94	0.84		-0.28	0.82	0.94	0.28	0.69	1.0	0.67	0.94	0.69	0.88
Other Liab	0.43	0.42	0.29	0.59	-0.19	-0.33	0.37	-0.19	0.0	0.07	0.01	0.03	-0.34	-0.16	-0.28	-0.28		-0.31	-0.42	0.81	-0.29	-0.26	0.02	-0.17	0.46	-0.34
Property Plant And Equipment Net	0.56	0.37	-0.87	-0.01	0.88	0.88	0.59	0.65	0.85	0.37	0.79	0.23	0.79	0.88	0.98	0.82	-0.31		0.72	0.23	0.92	0.77	0.61	0.87	0.51	0.97
Net Debt	0.5	0.22	-0.89	-0.12	0.87	0.89	0.59	0.75	0.77	0.13	0.65	0.36	0.78	0.85	0.73	0.94	-0.42	0.72		0.11	0.59	0.95	0.64	0.85	0.55	0.77
Non Current Assets Total	0.86	0.73	-0.27	0.62	0.38	0.24	0.81	0.24	0.55	0.3	0.49	0.3	0.18	0.41	0.27	0.28	0.81	0.23	0.11		0.24	0.3	0.51	0.39	0.85	0.2
Non Currrent Assets Other	0.61	0.52	-0.74	-0.01	0.75	0.76	0.57	0.49	0.75	0.5	0.71	0.42	0.8	0.77	0.92	0.69	-0.29	0.92	0.59	0.24		0.65	0.72	0.74	0.48	0.83
Long Term Debt	0.64	0.31	-0.95	0.1	0.95	0.93	0.74	0.81	0.91	0.15	0.85	0.28	0.82	0.93	0.8	1.0	-0.26	0.77	0.95	0.3	0.65		0.68	0.93	0.7	0.84
Cash And Short Term Investments	0.84	0.83	-0.61	0.26	0.69	0.63	0.72	0.33	0.7	0.62	0.58	0.85	0.65	0.73	0.67	0.67	0.02	0.61	0.64	0.51	0.72	0.68		0.69	0.67	0.52
Common Stock Total Equity	0.7	0.47	-0.97	0.09	1.0	0.97	0.74	0.8	0.96	0.3	0.88	0.28	0.74	1.0	0.89	0.94	-0.17	0.87	0.85	0.39	0.74	0.93	0.69		0.68	0.91
Non Current Liabilities Total	0.93	0.6	-0.64	0.5	0.69	0.58	0.99	0.56	0.8	0.21	0.75	0.33	0.59	0.7	0.54	0.69	0.46	0.51	0.55	0.85	0.48	0.7	0.67	0.68		0.53
Property Plant And Equipment Gross	0.52	0.25	-0.94	-0.03	0.93	0.93	0.6	0.78	0.89	0.23	0.86	0.07	0.79	0.91	0.95	0.88	-0.34	0.97	0.77	0.2	0.83	0.84	0.52	0.91	0.53

Click cells to compare fundamentals

Amicus Therapeutics Account Relationship Matchups

Amicus Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	886.5M	905.1M	724.2M	777.9M	785.0M	469.8M
Total Stockholder Equity	286.4M	307.4M	123.0M	160.2M	194.0M	170.7M
Retained Earnings	(2.0B)	(2.3B)	(2.5B)	(2.7B)	(2.7B)	(2.6B)
Other Assets	51.3M	65.4M	47.4M	42.2M	48.6M	41.8M
Common Stock Shares Outstanding	258.9M	271.4M	289.1M	295.2M	304.4M	319.6M
Liabilities And Stockholders Equity	886.5M	905.1M	724.2M	777.9M	785.0M	491.9M
Other Stockholder Equity	2.3B	2.6B	2.7B	2.8B	2.9B	3.1B
Total Liab	600.1M	597.8M	601.1M	617.7M	591.0M	299.1M
Other Current Liab	87.7M	103.5M	100.6M	131.8M	109.2M	114.7M
Total Current Liabilities	129.7M	146.0M	139.0M	167.7M	148.7M	156.1M
Accounts Payable	17.1M	21.5M	15.4M	15.1M	12.9M	20.8M
Cash	163.2M	245.2M	148.8M	247.0M	213.8M	224.4M
Short Term Investments	320.0M	237.3M	144.8M	39.2M	36.2M	34.4M
Other Current Assets	59.4M	69.7M	40.2M	49.5M	34.9M	18.0M
Common Stock	2.7M	2.8M	2.8M	2.9M	2.9M	3.1M
Property Plant Equipment	47.7M	43.9M	42.5M	30.8M	35.4M	37.2M
Short Long Term Debt Total	441.7M	440.1M	452.1M	445.1M	443.6M	465.8M
Other Liab	41.9M	35.6M	19.1M	18.5M	21.3M	20.2M
Property Plant And Equipment Net	67.2M	63.1M	60.3M	58.0M	51.7M	54.2M
Net Debt	278.5M	194.9M	303.3M	198.1M	229.9M	241.4M
Non Current Assets Total	307.1M	308.3M	300.4M	294.8M	280.3M	209.7M
Non Currrent Assets Other	19.1M	24.4M	10.0M	18.6M	13.6M	7.4M
Long Term Debt	389.3M	389.4M	392.0M	387.9M	390.1M	409.6M
Cash And Short Term Investments	483.3M	482.5M	293.6M	286.2M	249.9M	252.5M
Common Stock Total Equity	2.6M	2.7M	2.8M	2.8M	3.2M	3.4M
Non Current Liabilities Total	470.5M	451.8M	462.1M	450.0M	442.3M	255.5M
Property Plant And Equipment Gross	67.2M	83.0M	82.6M	83.4M	80.4M	84.5M
Total Current Assets	579.5M	596.8M	423.8M	483.1M	504.7M	306.8M
Accumulated Other Comprehensive Income	8.2M	5.0M	(12.1M)	5.2M	5.1M	5.3M
Short Term Debt	13.7M	14.8M	17.1M	8.3M	8.5M	7.2M
Net Tangible Assets	255.6M	65.6M	86.6M	(97.8M)	(112.4M)	(106.8M)
Net Receivables	46.9M	52.7M	66.2M	87.6M	101.1M	106.2M
Retained Earnings Total Equity	(1.8B)	(2.0B)	(2.3B)	(2.5B)	(2.3B)	(2.2B)
Capital Surpluse	2.2B	2.3B	2.6B	2.7B	3.1B	1.7B
Inventory	19.6M	26.8M	23.8M	59.7M	118.8M	124.7M
Deferred Long Term Liab	14.0M	12.3M	10.8M	9.6M	8.6M	8.2M
Non Current Liabilities Other	68.9M	51.6M	60.5M	13.3M	7.1M	6.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.18)

Revenue Per Share

1.736

Quarterly Revenue Growth

0.301

Return On Assets

0.0272

Return On Equity

(0.32)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amicus Historical Balance Sheet

Amicus Therapeutics Inventory

124.72 Million

About Amicus Balance Sheet Analysis

Amicus Therapeutics Balance Sheet Chart

Net Tangible Assets

Capital Lease Obligations

Amicus Therapeutics balance sheet Correlations

Amicus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amicus Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Common Stock Total Equity	+ 1.0	Common Stock Shares Outstanding
Common Stock Total Equity	+ 1.0	Common Stock
Long Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Total Liab
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding

Common Stock Shares Outstanding	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Short Long Term Debt Total	- 0.97	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Long Term Debt	- 0.95	Retained Earnings